PIERIS PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
PIERIS PHARMACEUTICALS INC. - More news...
PIERIS PHARMACEUTICALS INC. - More news...
- Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
- PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.
- Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
- Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
- Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
- Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
- Thinking about buying stock in Soleno Therapeutics, Lovesac, Pieris Pharmaceuticals, Lithium Americas, or Fisker?
- Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
- Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
- Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
- Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
- Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
- Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
- Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
- Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
- Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
- Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
- Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
- Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
- Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
- Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
- Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
- Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
- Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
- Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
- Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
- Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
